

# Trevor W Hambley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7752624/publications.pdf>

Version: 2024-02-01

184  
papers

10,173  
citations

30070

54  
h-index

38395

95  
g-index

200  
all docs

200  
docs citations

200  
times ranked

9001  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel polyamide amidine anthraquinone platinum(II) complexes: cytotoxicity, cellular accumulation, and fluorescence distributions in 2D and 3D cell culture models. <i>Journal of Biological Inorganic Chemistry</i> , 2021, 26, 217-233.	2.6	2
2	Warburg Effect Targeting Co(III) Cytotoxin Chaperone Complexes. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2678-2690.	6.4	9
3	Platinum binding preferences dominate the binding of novel polyamide amidine anthraquinone platinum(II) complexes to DNA. <i>Dalton Transactions</i> , 2021, 50, 17945-17952.	3.3	2
4	Water-Soluble $\pm$ -Amino Acid Complexes of Molybdenum as Potential Antidotes for Cyanide Poisoning: Synthesis and Catalytic Studies of Threonine, Methionine, Serine, and Leucine Complexes. <i>Inorganic Chemistry</i> , 2020, 59, 18190-18204.	4.0	6
5	The effect of charge on the uptake and resistance to reduction of platinum(IV) complexes in human serum and whole blood models. <i>Metallomics</i> , 2020, 12, 1599-1615.	2.4	8
6	<i>trans</i> -Platinum(IV) pro-drugs that exhibit unusual resistance to reduction by endogenous reductants and blood serum but are rapidly activated inside cells: $^1\text{H}$ NMR and XANES spectroscopy study. <i>Dalton Transactions</i> , 2020, 49, 7722-7736.	3.3	21
7	A Warburg effect targeting vector designed to increase the uptake of compounds by cancer cells demonstrates glucose and hypoxia dependent uptake. <i>PLoS ONE</i> , 2019, 14, e0217712.	2.5	12
8	Element 78 – Platinum. <i>Australian Journal of Chemistry</i> , 2019, 72, 649.	0.9	0
9	The impact of highly electron withdrawing carboxylato ligands on the stability and activity of platinum(IV) pro-drugs. <i>Inorganica Chimica Acta</i> , 2019, 494, 84-90.	2.4	8
10	Transporter and protease mediated delivery of platinum complexes for precision oncology. <i>Journal of Biological Inorganic Chemistry</i> , 2019, 24, 457-466.	2.6	17
11	The reduction of <i>cis</i> -platinum(IV) complexes by ascorbate and in whole human blood models using $^1\text{H}$ NMR and XANES spectroscopy. <i>Metallomics</i> , 2019, 11, 686-695.	2.4	23
12	Modulating the Cellular Uptake of Fluorescently Tagged Substrates of Prostate-Specific Antigen before and after Enzymatic Activation. <i>Bioconjugate Chemistry</i> , 2019, 30, 124-133.	3.6	4
13	A ratiometric iron probe enables investigation of iron distribution within tumour spheroids. <i>Metallomics</i> , 2018, 10, 553-556.	2.4	10
14	A fluorescent probe for investigating metabolic stability of active transplatin analogues. <i>Sensors and Actuators B: Chemical</i> , 2018, 255, 2721-2724.	7.8	15
15	Harnessing the properties of cobalt coordination complexes for biological application. <i>Coordination Chemistry Reviews</i> , 2018, 375, 221-233.	18.8	84
16	Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells. <i>Journal of Biological Inorganic Chemistry</i> , 2017, 22, 765-774.	2.6	35
17	The influence of the ethane-1,2-diamine ligand on the activity of a monofunctional platinum complex. <i>Journal of Inorganic Biochemistry</i> , 2017, 177, 328-334.	3.5	10
18	The influence of the ancillary ligand on the potential of cobalt(III) complexes to act as chaperones for hydroxamic acid-based drugs. <i>Dalton Transactions</i> , 2017, 46, 15897-15907.	3.3	14

#	ARTICLE	IF	CITATIONS
19	A ratiometric fluorescent sensor for the mitochondrial copper pool. <i>Metallomics</i> , 2016, 8, 915-919.	2.4	32
20	A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo. <i>Cell and Bioscience</i> , 2016, 6, 9.	4.8	27
21	Radiosynthesis and "click"™ conjugation of ethynyl- <sup>18</sup> F-fluorobenzene " an improved [ <sup>18</sup> F]synthon for indirect radiolabeling. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 473-478.	1.0	13
22	Cobalt(III) Chaperone Complexes of Curcumin: Photoreduction, Cellular Accumulation and Light-Selective Toxicity towards Tumour Cells. <i>Chemistry - A European Journal</i> , 2015, 21, 15224-15234.	3.3	79
23	Fluorescent sensing of monofunctional platinum species. <i>Chemical Communications</i> , 2015, 51, 6312-6314.	4.1	24
24	Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. <i>Metallomics</i> , 2014, 6, 2126-2133.	2.4	123
25	The composition and end-group functionality of sterically stabilized nanoparticles enhances the effectiveness of co-administered cytotoxins. <i>Biomaterials Science</i> , 2013, 1, 1260-1272.	5.4	23
26	Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study. <i>Chemical Science</i> , 2013, 4, 3731.	7.4	130
27	Facile Preparation of Mono-, Di- and Mixed-Carboxylato Platinum(IV) Complexes for Versatile Anticancer Prodrug Design. <i>Chemistry - A European Journal</i> , 2013, 19, 1672-1676.	3.3	108
28	Influence of Equatorial and Axial Carboxylato Ligands on the Kinetic Inertness of Platinum(IV) Complexes in the Presence of Ascorbate and Cysteine and within DLD-1 Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8757-8764.	6.4	85
29	Dual Targeting of Hypoxic and Acidic Tumor Environments with a Cobalt(III) Chaperone Complex. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 11013-11021.	6.4	85
30	Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES). <i>Metallomics</i> , 2012, 4, 568.	2.4	56
31	Getting to the core of platinum drug bio-distributions: the penetration of anti-cancer platinum complexes into spheroid tumour models. <i>Metallomics</i> , 2012, 4, 1209.	2.4	56
32	Systematic differences in electrochemical reduction of the structurally characterized anti-cancer platinum(IV) complexes [Pt{((p- <i>HC6F4</i> )NCH <sub>2</sub> ) <sub>2</sub> -(pyridine)2Cl <sub>2</sub> }, [Pt{((p- <i>HC6F4</i> )NCH <sub>2</sub> ) <sub>2</sub> (pyridine)2(OH)2}], and [Pt{((p- <i>HC6F4</i> )NCH <sub>2</sub> ) <sub>2</sub> (pyridine)2(OH)Cl}]. <i>Journal of Inorganic Biochemistry</i> , 2012, 115, 226-239.	3.5	32
33	Structural and anticancer properties of hydrogen bonded diphenyl phosphate adducts of Pt(IV) complexes: The importance of pKa matching. <i>Journal of Inorganic Biochemistry</i> , 2012, 115, 220-225.	3.5	2
34	Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate. <i>Chemical Communications</i> , 2012, 48, 847-849.	4.1	174
35	The use of spectroscopic imaging and mapping techniques in the characterisation and study of DLD-1 cell spheroid tumour models. <i>Integrative Biology (United Kingdom)</i> , 2012, 4, 1072-1080.	1.3	32
36	Effects of Enzymatic Activation on the Distribution of Fluorescently Tagged MMP-2 Cleavable Peptides in Cancer Cells and Spheroids. <i>Bioconjugate Chemistry</i> , 2012, 23, 1110-1118.	3.6	13

#	ARTICLE	IF	CITATIONS
37	Cobalt complexes with tripodal ligands: implications for the design of drug chaperones. Dalton Transactions, 2012, 41, 11293.	3.3	50
38	Visualising the hypoxia selectivity of cobalt(III) prodrugs. Chemical Science, 2011, 2, 2135.	7.4	54
39	The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity. Dalton Transactions, 2011, 40, 344-347.	3.3	29
40	Platinum-oxazoline complexes as anti-cancer agents: syntheses, characterisation and initial biological studies. MedChemComm, 2011, 2, 274.	3.4	20
41	Stabilization of Triam(m)inechloridoplatinum Complexes by Oxidation to PtIV. Australian Journal of Chemistry, 2011, 64, 273.	0.9	9
42	Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells. BMC Cell Biology, 2011, 12, 36.	3.0	6
43	Inhibition of experimental colorectal cancer and reduction in renal and gastrointestinal toxicities by copper(II)-indomethacin in rats. Cancer Chemotherapy and Pharmacology, 2010, 66, 755-764.	2.3	43
44	Syntheses and structures of N-polyfluorophenyl- and N,N'-bis(polyfluorophenyl)ethane-1,2-diaminato(1-) Tj ETQq0,0 0 rgBT /Overlock	1.7	6
45	Synthesis, characterisation and in vitro cytotoxicity studies of a series of chiral platinum(II) complexes based on the 2-aminomethylpyrrolidine ligand: X-ray crystal structure of [PtCl <sub>2</sub> (R-dimepyrr)] (R-dimepyrr=N-dimethyl-2(R)-aminomethylpyrrolidine). European Journal of Medicinal Chemistry, 2009, 44, 2807-2814.	5.5	14
46	Enantioselectivity and stereoselectivity in the reactions of the enantiomers of the platinum complex [PtCl <sub>2</sub> (ahaz)] (ahaz=3(R)- or 3(S)-aminohexahydroazepine) with DNA. Journal of Inorganic Biochemistry, 2009, 103, 168-173.	3.5	12
47	Fluorescent analogues of quinoline reveal amine ligand loss from cis and trans platinum(II) complexes in cancer cells. Journal of Inorganic Biochemistry, 2009, 103, 1120-1125.	3.5	21
48	Accumulation of an anthraquinone and its platinum complexes in cancer cell spheroids: the effect of charge on drug distribution in solid tumour models. Chemical Communications, 2009, , 2673.	4.1	68
49	Investigations using fluorescent ligands to monitor platinum(IV) reduction and platinum(II) reactions in cancer cells. Dalton Transactions, 2009, , 3092.	3.3	66
50	Platinum Drug Distribution in Cancer Cells and Tumors. Chemical Reviews, 2009, 109, 4911-4920.	47.7	314
51	Is Anticancer Drug Development Heading in the Right Direction?. Cancer Research, 2009, 69, 1259-1262.	0.9	145
52	Iron(III) complexes of fluorescent hydroxamate ligands: preparation, properties, and cellular processing. Dalton Transactions, 2009, , 10787.	3.3	15
53	Identification by NMR Spectroscopy of the Two Stereoisomers of the Platinum Complex [PtCl <sub>2</sub> (S-ahaz)] (S-ahaz = 3(S)-Aminohexahydroazepine) Bound to a DNA 14-mer Oligonucleotide. NMR Evidence of Structural Alteration of a Platinated AA-T-rich 14-mer DNA Duplex. Inorganic Chemistry, 2009, 48, 3047-3056.	4.0	9
54	Binding of [Pt(1C3)(dien)] <sup>2+</sup> to the duplex DNA oligonucleotide 5'-d(TGGCCA)-3': the effect of an appended positive charge on the orientation and location of anthraquinone intercalation. Dalton Transactions, 2009, , 932-939.	3.3	15

#	ARTICLE	IF	CITATIONS
55	Cellular uptake and distribution of cobalt complexes of fluorescent ligands. <i>Journal of Biological Inorganic Chemistry</i> , 2008, 13, 861-871.	2.6	41
56	[ <sup>1</sup> H, <sup>15</sup> N] Heteronuclear Single Quantum Coherence NMR Study of the Mechanism of Aquation of Platinum(IV) Ammine Complexes. <i>Inorganic Chemistry</i> , 2008, 47, 7673-7680.	4.0	41
57	Physiological Targeting to Improve Anticancer Drug Selectivity. <i>Australian Journal of Chemistry</i> , 2008, 61, 647.	0.9	24
58	Developing new metal-based therapeutics: challenges and opportunities. <i>Dalton Transactions</i> , 2007, , 4929.	3.3	299
59	Bioreductive activation and drug chaperoning in cobalt pharmaceuticals. <i>Dalton Transactions</i> , 2007, , 3983.	3.3	164
60	Metal-Based Therapeutics. <i>Science</i> , 2007, 318, 1392-1393.	12.6	194
61	Database Analysis of Transition Metal Carbonyl Bond Lengths: An Insight into the Periodicity of $\pi$ Back-Bonding, $\sigma$ Donation, and the Factors Affecting the Electronic Structure of the $TM-\pi-C\equiv O$ Moiety. <i>Organometallics</i> , 2007, 26, 2815-2823.	2.3	56
62	Elemental Tomography of Cancer-Cell Spheroids Reveals Incomplete Uptake of Both Platinum(II) and Platinum(IV) Complexes. <i>Journal of the American Chemical Society</i> , 2007, 129, 13400-13401.	13.7	56
63	DFT Study of the Systematic Variations in Metal-Ligand Bond Lengths of Coordination Complexes: The Crucial Role of the Condensed Phase. <i>Inorganic Chemistry</i> , 2007, 46, 8238-8244.	4.0	65
64	Using XANES to Monitor the Oxidation State of Cobalt Complexes. <i>Australian Journal of Chemistry</i> , 2007, 60, 180.	0.9	18
65	Basis for Design and Development of Platinum(IV) Anticancer Complexes. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3403-3411.	6.4	414
66	Studies of a Cobalt(III) Complex of the MMP Inhibitor Marimastat: A Potential Hypoxia-Activated Prodrug. <i>Chemistry - A European Journal</i> , 2007, 13, 2974-2982.	3.3	121
67	Towards bioreductively activated prodrugs: Fe(III) complexes of hydroxamic acids and the MMP inhibitor marimastat. <i>Journal of Inorganic Biochemistry</i> , 2007, 101, 396-403.	3.5	46
68	Models of hypoxia activated prodrugs: Co(III) complexes of hydroxamic acids. <i>Dalton Transactions</i> , 2006, , 1895.	3.3	59
69	Platinum(IV) Analogues of AMD473 ( <i>cis</i> -[PtCl <sub>2</sub> (NH <sub>3</sub> )(2-picoline)]): Preparative, Structural, and Electrochemical Studies. <i>Inorganic Chemistry</i> , 2006, 45, 6317-6322.	4.0	35
70	The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours. <i>Journal of Structural Biology</i> , 2006, 155, 38-44.	2.8	90
71	Kinetics and structural aspects of the cisplatin interactions with guanine: A quantum mechanical description. <i>International Journal of Quantum Chemistry</i> , 2006, 106, 2129-2144.	2.0	35
72	XANES investigation of the Co oxidation state in solution and in cancer cells treated with Co(III) complexes. <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 963-971.	3.5	48

#	ARTICLE	IF	CITATIONS
73	DNA-binding and molecular mechanics modelling studies of the bulky chiral platinum(II) complex [PtCl <sub>2</sub> (mepyr)] (mepyr=N-methyl-2-aminomethylpyrrolidine). <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 1965-1973.	3.5	10
74	The Discovery and Development of Cisplatin. <i>Journal of Chemical Education</i> , 2006, 83, 728.	2.3	403
75	DNA adducts of the enantiomers of the Pt(II) complexes of the ahaz ligand (ahaz=3-amino-hexahydroazepine) and recognition of these adducts by HMG domain proteins. <i>Biochemical and Biophysical Research Communications</i> , 2005, 332, 1034-1041.	2.1	10
76	Nuclear Magnetic Resonance Analysis of Indomethacin-Induced Gastric Ulcers. <i>Chemical Research in Toxicology</i> , 2005, 18, 123-128.	3.3	15
77	Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models. <i>Biochemical Pharmacology</i> , 2004, 67, 17-30.	4.4	49
78	The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1614-1624.	3.5	112
79	NMR Spectroscopic Characterization of Copper(II) and Zinc(II) Complexes of Indomethacin. <i>Inorganic Chemistry</i> , 2004, 43, 2943-2946.	4.0	34
80	Platinum(IV) Anticancer Complexes. , 2004, , 297-322.		39
81	Copper and zinc complexes as antiinflammatory drugs. <i>Metal Ions in Biological Systems</i> , 2004, 41, 253-77.	0.4	10
82	The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells. <i>Journal of Biological Inorganic Chemistry</i> , 2003, 8, 726-732.	2.6	143
83	Structural Measure of Metal-Ligand Covalency from the Bonding in Carboxylate Ligands. <i>Inorganic Chemistry</i> , 2003, 42, 2833-2835.	4.0	40
84	The preparation and characterisation of cyclam/anthraquinone macrocyclic/intercalator complexes and their interactions with DNA. <i>Dalton Transactions</i> , 2003, , 2728-2736.	3.3	28
85	XAFS Studies of Anti-Inflammatory Dinuclear and Mononuclear Zn(II) Complexes of Indomethacin. <i>Inorganic Chemistry</i> , 2003, 42, 8557-8566.	4.0	24
86	Cationic Iridium(I) Complexes as Catalysts for the Alcoholysis of Silanes. <i>Organometallics</i> , 2003, 22, 2387-2395.	2.3	116
87	Investigations into the Interactions between DNA and Conformationally Constrained Pyridylamineplatinum(II) Analogues of AMD473. <i>Inorganic Chemistry</i> , 2003, 42, 3582-3590.	4.0	27
88	The first examples of platinum amine hydroxamate complexes: structures and biological activity. <i>Dalton Transactions</i> , 2003, , 1596-1600.	3.3	22
89	Gastrointestinal Toxicity, Antiinflammatory Activity, and Superoxide Dismutase Activity of Copper and Zinc Complexes of the Antiinflammatory Drug Indomethacin. <i>Chemical Research in Toxicology</i> , 2003, 16, 28-37.	3.3	86
90	XANES Determination of the Platinum Oxidation State Distribution in Cancer Cells Treated with Platinum(IV) Anticancer Agents. <i>Journal of the American Chemical Society</i> , 2003, 125, 7524-7525.	13.7	135

#	ARTICLE	IF	CITATIONS
91	The electron density in flavones I. Baicalein. <i>New Journal of Chemistry</i> , 2003, 27, 1392-1398.	2.8	20
92	Insights into Pt(II)-Hydroxamate Bonding Through the Crystal Structures of DMSO Complexes. <i>Australian Journal of Chemistry</i> , 2003, 56, 45.	0.9	4
93	Electrochemistry, Protein Binding and Crystal Structures of Platinum(II) and Platinum(IV) Carboxylato Complexes. <i>Australian Journal of Chemistry</i> , 2002, 55, 699.	0.9	19
94	Structural Investigations of Palladium(II) and Platinum(II) Complexes of Salicylhydroxamic Acid. <i>Inorganic Chemistry</i> , 2002, 41, 1223-1228.	4.0	35
95	Minor groove intercalation of $\lambda^2$ -[Ru(Me <sub>2</sub> phen)2dppz] <sup>2+</sup> to the hexanucleotide d(GTCGAC) <sub>2</sub> . <i>Dalton Transactions RSC</i> , 2002, , 849.	2.3	91
96	The stereospecific synthesis of $\lambda^2$ -{dipyrido[3,2-a:2'-b]pyridine}(6,7,8,9-tetrahydro)phenazine[N,N'-di(2-picolyl)-2,5-dimethyl-2S,5S-diaminocyclohexane]ruthenium(II) and related $\lambda^2$ -isomers. <i>Dalton Transactions RSC</i> , 2002, , 4666.	2.3	9
97	Insights into bonding and hydrogen bond directionality in thioacetamide from the experimental charge distribution. <i>Perkin Transactions II RSC</i> , 2002, , 235-239.	1.1	20
98	Synthesis, spectroscopy, and theoretical studies of platinum(ii) phosphate complexes. <i>Dalton Transactions RSC</i> , 2002, , 1898.	2.3	9
99	Stereospecificity and Enantioselectivity in the Binding of the Platinum(II) Complex [PtCl <sub>2</sub> (tmdz)] (tmdz=5,5,7-Trimethyl-1,4-diazacycloheptane) to Dinucleotides and Oligonucleotides. <i>Chemistry - A European Journal</i> , 2002, 8, 5486-5493.	3.3	4
100	Studies of the binding of a series of platinum(IV) complexes to plasma proteins. <i>Journal of Inorganic Biochemistry</i> , 2002, 88, 260-267.	3.5	58
101	Preparation and cell growth inhibitory activity of [PtR <sub>2</sub> L <sub>2</sub> ] (R=polyfluorophenyl, L <sub>2</sub> =diene,) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50</i> [Pt(C <sub>6</sub> F <sub>5</sub> ) <sub>2</sub> (cis-chxn)]. <i>Journal of Inorganic Biochemistry</i> , 2002, 89, 293-301.	3.5	24
102	Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. <i>Coordination Chemistry Reviews</i> , 2002, 232, 95-126.	18.8	469
103	Platinum(IV) antitumour compounds: their bioinorganic chemistry. <i>Coordination Chemistry Reviews</i> , 2002, 232, 49-67.	18.8	561
104	Structure, Stability, and Interconversion Barriers of the Rotamers of cis-[PtII(Cl)(quinoline) <sub>2</sub> ] and cis-[PtII(Cl)(3-bromoquinoline)(quinoline)] from X-ray Crystallography, NMR Spectroscopy and Molecular Mechanics Evidence. <i>Inorganic Chemistry</i> , 2001, 40, 3048-3054.	4.0	17
105	Platinum binding to DNA: structural controls and consequences. <i>Dalton Transactions RSC</i> , 2001, , 2711-2718.	2.3	128
106	Structure and dynamics of a platinum(II) aminophosphine complex and its nucleobase adducts. <i>Dalton Transactions RSC</i> , 2001, , 362-372.	2.3	22
107	Isomer formation in the binding of [PtCl <sub>2</sub> (cis-cyclohexane-1,3-diamine)] to oligonucleotides and the X-ray crystal structure of [PtCl <sub>2</sub> (cis-cyclohexane-1,3-diamine)]·dimethylformamide. <i>Dalton Transactions RSC</i> , 2001, , 2769-2774.	2.3	6
108	Polypyrazolylmethane complexes of ruthenium. <i>Dalton Transactions RSC</i> , 2001, , 1959-1965.	2.3	34

#	ARTICLE	IF	CITATIONS
109	Dinuclear Chromium(V) Amino Acid Complexes from the Reduction of Chromium(VI) in the Presence of Amino Acid Ligands: A XAFS Characterization of a Chromium(V) Amino Acid Complex. <i>Inorganic Chemistry</i> , 2001, 40, 5097-5105.	4.0	21
110	Determination of the Structures of Antiinflammatory Copper(II) Dimers of Indomethacin by Multiple-Scattering Analyses of X-ray Absorption Fine Structure Data. <i>Inorganic Chemistry</i> , 2001, 40, 1295-1302.	4.0	54
111	Preparation and characterization of dinuclear copper(II)-indomethacin anti-inflammatory drugs. <i>Inorganica Chimica Acta</i> , 2001, 324, 150-161.	2.4	71
112	Calculation of the Hydrophobicity of Platinum Drugs. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 472-474.	6.4	80
113	Steric control of stereoselective interactions between the platinum(II) complex [PtCl <sub>2</sub> (1,4-diazacycloheptane)] and DNA: comparison with cis-[PtCl <sub>2</sub> (NH <sub>3</sub> ) <sub>2</sub> ] and [PtCl <sub>2</sub> (ethane-1,2-diamine)] using DNA binding and molecular modeling studies. <i>Journal of Biological Inorganic Chemistry</i> , 2001, 6, 534-542.	2.6	14
114	Macrocyclic ligand design. X-Ray, DFT and solution studies of the effect of N-methylation and N-benzylation of 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane on its affinity for selected transition and post-transition metal ions. <i>Dalton Transactions RSC</i> , 2001, , 614-620.	2.3	58
115	The preparation, characterisation, and DNA adduct profile of 2-amino-2-methyl-3-butanoneoximedichloroplatinum(II), a platinum(II) complex designed to bind to GpA sequences of DNA. <i>Journal of Inorganic Biochemistry</i> , 2000, 78, 55-62.	3.5	12
116	Rates of platination of -AG- and -GA- containing double-stranded oligonucleotides: effect of chloride concentration. <i>Journal of Inorganic Biochemistry</i> , 2000, 79, 167-172.	3.5	27
117	Increased targeting of adenine-rich sequences by (2-amino-2-methyl-3-butanone) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 427 T <i>Inorganic Chemistry</i> , 2000, 5, 675-681.	2.6	20
118	Crystal Structures of Tris(hydroxamato) Complexes of Iron(III). <i>Australian Journal of Chemistry</i> , 2000, 53, 879.	0.9	19
119	Conformations of cyclic octapeptides and the influence of heterocyclic ring constraints upon calcium binding. <i>Perkin Transactions II RSC</i> , 2000, , 323-331.	1.1	36
120	Slowing of Cisplatin Aquation in the Presence of DNA but Not in the Presence of Phosphate: A Improved Understanding of Sequence Selectivity and the Roles of Monoaquated and Diaquated Species in the Binding of Cisplatin to DNA. <i>Inorganic Chemistry</i> , 2000, 39, 5603-5613.	4.0	154
121	Characterization and X-ray Absorption Spectroscopic Studies of Bis[quinato(2-)]oxochromate(V)1. <i>Inorganic Chemistry</i> , 2000, 39, 990-997.	4.0	38
122	Syntheses and Characterization of Anti-inflammatory Dinuclear and Mononuclear Zinc Indomethacin Complexes. Crystal Structures of [Zn <sub>2</sub> (Indomethacin) <sub>4</sub> (L) <sub>2</sub> ] (L = N,N-Dimethylacetamide, Pyridine,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2000, 39, 3742-3748.	4.0	158
123	Three new platinum(II)-dipeptide complexes. <i>Journal of Inorganic Biochemistry</i> , 1999, 73, 173-186.	3.5	19
124	Rhodium complexes containing bidentate imidazolyl ligands: synthesis and structure. <i>Journal of Organometallic Chemistry</i> , 1999, 588, 69-77.	1.8	45
125	Synthesis, Structure, Biological Activity, and DNA Binding of Platinum(II) Complexes of the Typetrans-[PtCl <sub>2</sub> (NH <sub>3</sub> )L] (L = Planar Nitrogen Base). Effect of L and Cis/Trans Isomerism on Sequence Specificity and Unwinding Properties Observed in Globally Platinated DNA. <i>Inorganic Chemistry</i> , 1999, 38, 3535-3542.	4.0	103
126	Anti-Inflammatory Dinuclear Copper(II) Complexes with Indomethacin. Synthesis, Magnetism and EPR Spectroscopy. Crystal Structure of the N,N-Dimethylformamide Adduct. <i>Inorganic Chemistry</i> , 1999, 38, 1736-1744.	4.0	129



#	ARTICLE	IF	CITATIONS
127	Butenynyl complexes of iron(II) containing the tripodal tetraphosphine ligand P(CH <sub>2</sub> CH <sub>2</sub> PMe <sub>2</sub> ) <sub>3</sub> . Journal of the Chemical Society Dalton Transactions, 1999, , 2557-2562.	1.1	13
128	Synthesis and some octahedral complexes of a chiral triaza macrocycle. Journal of the Chemical Society Dalton Transactions, 1999, , 1975-1980.	1.1	15
129	van der Waals Radii of Pt(II) and Pd(II) in Molecular Mechanics Models and an Analysis of Their Relevance to the Description of Axial M-Å-H(Å-C), M-Å-H(Å-N), M-Å-S, and M-Å-M (M = Pd(II) or Pt(II)) Interactions. Inorganic Chemistry, 1998, 37, 3767-3774.	4.0	98
130	[Pt <sub>2</sub> Cl <sub>2</sub> (μ <sub>2</sub> -O <sub>2</sub> ) <sub>2</sub> ([9]aneN <sub>3</sub> ) <sub>2</sub> ]Cl <sub>2</sub> : A Novel Platinum(IV) Dimer with Two Bridging Peroxo Ligands that Provides Insight into the Mechanism of Aerial Oxidation of Platinum(II). Inorganic Chemistry, 1998, 37, 5408-5409.	4.0	35
131	Modification of Platinum(II) Antitumor Complexes with Sulfur Ligands. 1. Synthesis, Structure, and Spectroscopic Properties of Cationic Complexes of the Types [PtCl(diamine)(L)]NO <sub>3</sub> and [{PtCl(diamine)} <sub>2</sub> (L-L)](NO <sub>3</sub> ) <sub>2</sub> (L = Monofunctional Thiourea Derivative; L-L = Bifunctional Thiourea) Tj ETQq1 1 0.784314 rgBT /Overlock 10	4.0	77
132	A <sup>1</sup> H NMR Study of the DNA Binding of Ruthenium(II) Polypyridyl Complexes. Inorganic Chemistry, 1998, 37, 3133-3141.	4.0	315
133	Rates of Platination of AG and GA Containing Double-Stranded Oligonucleotides: Insights into Why Cisplatin Binds to GG and AG but Not GA Sequences in DNA. Journal of the American Chemical Society, 1998, 120, 11380-11390.	13.7	63
134	Steric Determinants of Pt/DNA Interactions and Anticancer Activity. Metal-Based Drugs, 1998, 5, 197-206.	3.8	2
135	The Dichloroplatinum(II) Complex of 5,5,7-Trimethyl-1,4-diazacycloheptane: Preparation, Crystal Structure and Binding to Nucleotides and DNA. Australian Journal of Chemistry, 1998, 51, 977.	0.9	6
136	Synthesis of novel ruthenium complexes containing bidentate imidazole-based ligands. Journal of the Chemical Society Dalton Transactions, 1997, , 2341-2346.	1.1	35
137	Chelate-ring-opened adducts of [Pt(en)(Me-Mal-O, O <sup>2-</sup> )] (en = ethane-1,2-diamine,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj ETQq1 1 0.784314 rgBT /Overlock 10 platinum anticancer agents. Journal of the Chemical Society Dalton Transactions, 1997, , 469-478.	1.1	22
138	Preparation, Characterization, DNA Binding, and in Vitro Cytotoxicity of the Enantiomers of the Platinum(II) Complexes N-Methyl-, N-Ethyl- and N,N-Dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II). Journal of Medicinal Chemistry, 1997, 40, 3508-3515.	6.4	34
139	Highly Diastereoselective Conjugate Addition of Lithiated <sup>13</sup> C-Crotonolactone (But-2-en-4-olide) to Cyclic Enones To Give Syn-Adducts: Application to a Brefeldin Synthesis. Journal of Organic Chemistry, 1997, 62, 4552-4553.	3.2	30
140	Preparation, DNA Binding, and in Vitro Cytotoxicity of a Pair of Enantiomeric Platinum(II) Complexes, [(R)- and (S)-3-Amino-6-hydroazepine]dichloro-platinum(II). Crystal Structure of the S-Enantiomer. Journal of Medicinal Chemistry, 1997, 40, 1090-1098.	6.4	65
141	The influence of structure on the activity and toxicity of Pt anti-cancer drugs. Coordination Chemistry Reviews, 1997, 166, 181-223.	18.8	331
142	Platination of A GG Site on Single-Stranded and Double-Stranded forms of A 14-Base Oligonucleotide with Diaqua Cisplatin followed by NMR and HPLC. Influence of the Platinum Ligands and Base Sequence on 5'-G Versus 3'-G Platination Selectivity. FEBS Journal, 1997, 249, 370-382.	0.2	68
143	Immobilization of Platinated and Iodinated Oligonucleotides on Carbon Nanotubes. Angewandte Chemie International Edition in English, 1997, 36, 2198-2200.	4.4	118
144	Immobilisierung von platinieren und iodierten DNA-Oligomeren an Kohlenstoff-Nanoröhren. Angewandte Chemie, 1997, 109, 2291-2294.	2.0	16

#	ARTICLE	IF	CITATIONS
145	Synthesis and exchange reactions of 5-alkyl-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acids. <i>Journal of Heterocyclic Chemistry</i> , 1997, 34, 1355-1367.	2.6	12
146	Dinuclear Platinum Complexes Form a Novel Intrastrand Adduct with d(GpG), anti-syn Conformation of the Macrochelate As Observed by NMR and Molecular Modeling. <i>Journal of the American Chemical Society</i> , 1996, 118, 9307-9313.	13.7	45
147	Combined NMR and Molecular Mechanics Study of the Isomers Formed in the Reaction of Dichloro(1,4-diazacycloheptane)platinum(II) with the Dinucleotide d(GpG). <i>Inorganic Chemistry</i> , 1996, 35, 4663-4668.	4.0	24
148	Oxidative Addition of the Dithiobis(formamidinium) Cation to Platinum(II) Chloro Am(m)ine Compounds: A Study on Structure, Spectroscopic Properties, Reactivity, and Cytotoxicity of a New Class of Platinum(IV) Complexes Exhibiting S-Thiourea Coordination. <i>Inorganic Chemistry</i> , 1996, 35, 4865-4872.	4.0	38
149	Doppelhelicale zweikernige Kupfer( $\text{I}$ )-Komplexe mit makrocyclischen Bis(dithiadiimin)-Liganden. <i>Angewandte Chemie</i> , 1995, 107, 2047-2050.	2.0	12
150	Double Helical Dinuclear Copper(I) Complexes of Macrocyclic Bis(dithiadiimine) Ligands. <i>Angewandte Chemie International Edition in English</i> , 1995, 34, 1883-1885.	4.4	32
151	The Directionality of d-Orbitals and Molecular-Mechanics Calculations of Octahedral Transition-Metal Compounds. <i>Helvetica Chimica Acta</i> , 1995, 78, 2042-2047.	1.6	68
152	Interpretation of Electronic and EPR Spectra of Copper(II) Amine Complexes: A Test of the MM-AOM Method. <i>Inorganic Chemistry</i> , 1995, 34, 3903-3911.	4.0	105
153	Analysis of warfarin enantiomers: Chromatographic separation of six stereoisomeric esters prepared from (?)-(1S,2R,4R)-endo-1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2-carboxylic acid. <i>Chirality</i> , 1994, 6, 670-680.	2.6	1
154	The preparation and in vivo activity of L- and D-O-methyl-methionine-dichloroplatinum(II). The crystal structure of the L-enantiomer. <i>Journal of Inorganic Biochemistry</i> , 1994, 55, 175-181.	3.5	9
155	DNA Binding of a Platinum(II) Complex Designed To Bind Interstrand but Not Intrastrand. <i>Journal of the American Chemical Society</i> , 1994, 116, 2673-2674.	13.7	34
156	The preparation and characterisation of some aminesulfoxidedichloroplatinum(II) complexes. <i>Journal of the Chemical Society Dalton Transactions</i> , 1993, , 3705.	1.1	15
157	Preparation, characterization, cytotoxicity, and mutagenicity of a pair of enantiomeric platinum(II) complexes with the potential to bind enantioselectively to DNA. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 3663-3668.	6.4	46
158	What Can Be Learnt from Computer-Generated Models of Interactions Between DNA and Pt(II) Based Anti-Cancer Drugs?. <i>Comments on Inorganic Chemistry</i> , 1992, 14, 1-26.	5.2	19
159	The synthesis and characterization of norbornylsilasesquioxanes. <i>Applied Organometallic Chemistry</i> , 1992, 6, 253-260.	3.5	44
160	Chiral Tetraamines Based on (S)-2-(Aminomethyl)pyrrolidine: Template synthesis and properties of copper(II) complexes. <i>Helvetica Chimica Acta</i> , 1992, 75, 145-152.	1.6	18
161	Molecular mechanics analysis of the stereochemical factors influencing monofunctional and bifunctional binding of cis-diamminedichloroplatinum(II) to adenine and guanine nucleobases in the sequences d(GpApGpG).cntdot.d(CpCpTpC) and d(GpGpApG).cntdot.d(CpTpCpC) of A- and B-DNA. <i>Inorganic Chemistry</i> , 1991, 30, 937-942.	4.0	79
162	Reactions of the cis-diamminediaquaplatinum(II) cation with glycnamide, N-glycylglycine, and N-(N-glycylglycyl)glycine. Crystal structure of a complex with two diammineplatinum(II) cations bound to glycylglycinate. <i>Inorganic Chemistry</i> , 1990, 29, 3562-3569.	4.0	40

#	ARTICLE	IF	CITATIONS
163	Energy-Minimized Structures and Calculated and Experimental Isomer Distributions in the Hexaamincobalt(III) system [Co(trap) <sub>2</sub> ] <sup>3+</sup> (trap = 1,2,3-propanetriamine). <i>Helvetica Chimica Acta</i> , 1988, 71, 1875-1880.	1.6	29
164	Steric contributions to the thermodynamics of electron transfer in cobalt(III) hexaamine complexes. <i>Inorganic Chemistry</i> , 1988, 27, 2496-2501.	4.0	65
165	Molecular mechanics analysis of the influence of interligand interactions on isomer stabilities and barriers to isomer interconversion in diammine- and bis(amine)bis(purine)platinum(II) complexes. <i>Inorganic Chemistry</i> , 1988, 27, 1073-1077.	4.0	63
166	Strain energy minimization study of the mechanism of, and the barrier to, conformational interconversion in five-membered diamine chelate rings. <i>Journal of Computational Chemistry</i> , 1987, 8, 651-657.	3.3	29
167	Template Synthesis, Crystal Structure, and Spectroscopic Characterization of [N,N'-Bis(2-pyridylmethylene)-1,3-diamino-2-methyl-2-nitropropane] copper(II) Perchlorate. <i>Helvetica Chimica Acta</i> , 1985, 68, 2332-2341.	1.6	22
168	Appendix 1: Glossary. , 0, , 293-296.		0
169	Appendix 2: Fundamental Constants, Units, and Conversion Factors. , 0, , 297-298.		0
170	Appendix 3: Software and Force Fields. , 0, , 299-299.		0
171	Appendix 4: Books on Molecular Modeling and Reviews on Inorganic Molecular Modeling. , 0, , 301-304.		0
172	Electron Transfer. , 0, , 149-157.		0
173	Electronic Effects. , 0, , 159-170.		0
174	Bioinorganic Chemistry. , 0, , 171-181.		0
175	Organometallics. , 0, , 183-193.		0
176	Compounds with s-, p-, and f-Block Elements. , 0, , 195-201.		0
177	The Model, the Rules, and the Pitfalls. , 0, , 205-213.		0
178	Molecular Modeling Methods in Brief. , 0, , 9-18.		0
179	Parameterization, Approximations and Limitations of Molecular Mechanics. , 0, , 19-59.		0
180	Computation. , 0, , 61-68.		0

#	ARTICLE	IF	CITATIONS
181	The Multiple Minima Problem. , 0, , 69-73.		0
182	Structural Aspects. , 0, , 79-88.		0
183	Stereoselectivities. , 0, , 89-109.		0
184	Metal Ion Selectivity. , 0, , 111-126.		0